Hereditary Angioedema Market

Global Hereditary Angioedema Market Size, Share and Trends Analysis Report, By Drug Class (C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, and Others), By Route of Administration (Intravenous, Subcutaneous Injection, and Oral), Forecast (2021-2027)
    Update Available - Forecast 2024-2030   

Published: Jul 2023 | Report Code: OMR2025975 | Category : Pharmaceuticals | Delivery Format: /

the global hereditary angioedema market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The major factor that is expected to boost the market growth includes the increasing awareness regarding rare diseases, such as hereditary angioedema (HAE). The increased funding for rare genetic diseases and orphan drugs by governments and private companies is also increasing the pharmaceutical companies' interest in developing drugs for hereditary angioedema, thus fuelling the market growth. For instance, in November 2020, Takeda Pharmaceutical entered an agreement for public funding of Takhzyro (Lanadelumab) in Canada to treat hereditary angioedema (HAE) patients. Hereditary angioedema is a disease characterized by recurrent episodes of severe swelling of the skin and mucous membranes. The swelling most commonly affects the arms, intestinal tract, legs, face, and airway and is usually not itchy. 

The increasing R&D and funding for orphan drug development and rare genetic disorders are expected to further fuel the growth of the global hereditary angioedema market. For instance, the Indian Ministry of Health and Family Welfare developed a National Policy to treat rare diseases in India to progressively expand India’s capabilities to treat rare diseases. Hence, the increased funding for R&D for new drugs is propelling the growth of the market during the forecast period. Moreover, pipeline drugs is expected to offer an opportunity for the growth of the global hereditary angioedema market. 

Recent Developments

In December 2021, BioCryst Pharmaceuticals was granted $350 million to support fund the global launch of Orladeyo (Berotralstat), an oral treatment for prevention of hereditary angioedema (HAE) swelling attacks. It works by inhibiting kallikrein activity.

In August 2020, the US Food and Drug Administration approved Takhzyro (Lanadelumab). It is the first monoclonal antibody that targets kallikrein and is indicated for treating patients aged 12 years and older with types I and II HAE.

Market Coverage

The market number available for – 2020-2027

Base year- 2020

Forecast period- 2021-2027

Segment Covered- 

o By Drug Class

o By Route of Administration

Regions covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

Competitive Landscape: Takeda Pharmaceutical Co. Ltd., Sanofi S.A., and Pharming Group, among others. 

Key questions addressed by the report

What is the market growth rate?

Which segment and region dominate the market in the base year?

Which segment and region will project the fastest growth in the market?

How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

Who is the leader in the market?

How are players addressing challenges to sustain growth?

Where is the investment opportunity?

Global Hereditary Angioedema Market Report by Segment

By Drug Class

  • C1 Esterase Inhibitor
  • Selective Bradykinin B2 Receptor Antagonist
  • Kallikrein Inhibitor
  • Others

By Route of Administration

  • Intravenous
  • Subcutaneous Injection
  • Oral

Global Hereditary Angioedema Market Report by Region

North America       

US

Canada

Europe

Germany

UK

France

Spain

Italy

Rest of Europe

Asia-Pacific    

China

Japan

India

Rest of Asia-Pacific

Rest of the World

Latin America

Middle East and Africa